Disease-modifying interventions in psychiatry
Australian & New Zealand Journal of Psychiatry · 26.10.2026
DOI: 10.1177/00048674261493034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian & New Zealand Journal of Psychiatry, online erschienen am 26.10.2026. Verfasst von Anna Baldes und 4 weiteren Autor:innen. Beteiligte Einrichtung: IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University and Barwon Health, Geelong, VIC…. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: national health and medical research council.
Abstract (Originalsprache)
Disease-modifying interventions do not just treat the symptoms of the disease but target the underlying disease process and natural course. The construct of disease-modifying treatments has transformed the care of disorders, like rheumatoid arthritis and multiple sclerosis, by shifting the focus to preventing end-organ damage rather than offering symptomatic treatment. As mental illness may have a chronic and progressive course, there is a need to consider whether any of our interventions may be disease-modifying. We, therefore, conducted a search using databases, including MEDLINE, EMBASE and PsycINFO, to identify peer-reviewed papers and grey literature related to the research question: ‘Which psychiatric treatments are disease-modifying?’ Disease-modifying properties were largely operationalised around end-organ changes, including structural brain changes evident on neuroimaging and cognition, and were reported for conventional psychotropics, as well as for novel pharmaceuticals and non-pharmacological interventions. Lithium and electroconvulsive therapy showed the greatest evidence as disease-modifying interventions. However, to establish this and identify potential other disease-modifying treatments, there needs to be a shift in the focus of psychiatric clinical trials to include primary outcomes that reflect disease progression and not just acute symptom burden. The potential disease-modifying properties of lithium and electroconvulsive therapy should spur the prioritisation of treatment higher up the algorithm, as well as the commencement of disease-modifying therapy as early as possible in the illness course to prevent adverse outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IMPACT - The Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Deakin University and Barwon Health, Geelong, VIC, Australia.
- Mental Health, Drugs and Alcohol Services, Barwon Health, VIC, Australia.
- Department of Paediatrics, Monash University, Clayton, VIC, Australia.
- Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia.
- Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
ORCID-Profile: Anna Baldes, Michael Berk
Förderung
- national health and medical research council
Zitieren
APA
Baldes, A., Tay, E., Agustini, B., Dodd, S., & Berk, M. (2026). Disease-modifying interventions in psychiatry. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/00048674261493034
Vancouver
Baldes A, Tay E, Agustini B, Dodd S, Berk M. Disease-modifying interventions in psychiatry. Australian & New Zealand Journal of Psychiatry. 2026. doi:10.1177/00048674261493034
BibTeX
@article{Baldes2026,
author = {Baldes, Anna and Tay, Emily and Agustini, Bruno and Dodd, Seetal and Berk, Michael},
title = {Disease-modifying interventions in psychiatry},
journal = {Australian & New Zealand Journal of Psychiatry},
year = {2026},
doi = {10.1177/00048674261493034}
}
EUVIMED